Arcutis Biotherapeutics, Inc.·4

Mar 2, 7:07 PM ET

Turney Patricia A. 4

4 · Arcutis Biotherapeutics, Inc. · Filed Mar 2, 2023

Insider Transaction Report

Form 4
Period: 2023-02-28
Turney Patricia A.
Senior VP, Manufacturing
Transactions
  • Sale

    Common Stock

    2023-02-28$16.17/sh936$15,13247,125 total
  • Sale

    Common Stock

    2023-03-02$15.82/sh1,414$22,36745,711 total
  • Sale

    Common Stock

    2023-03-02$16.52/sh18$29745,693 total
Footnotes (4)
  • [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
  • [F2]The transaction was executed in multiple trades in prices ranging from $15.990 to $16.320, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F3]Includes 1,617 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2022.
  • [F4]The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4